Business context and reporting period
Filing identity: The request metadata names HYPERION DEFI, INC., but the supplied Form 10-Q is for Eyenovia, Inc. It covers the quarter ended September 30, 2019 and was signed November 13, 2019. Eyenovia is a clinical-stage ophthalmic biopharmaceutical company developing microdose therapies delivered using its Optejet technology. It had no product revenue.
Financial results and liquidity
| Metric | Q3 2019 / September 30, 2019 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None reported |
| Net loss | $4.65 million for Q3; $15.92 million for nine months | $4.32 million for Q3 2018; $11.07 million for nine months 2018 |
| Operating expenses | $4.69 million for Q3; $16.02 million for nine months | $4.32 million for Q3 2018; $11.07 million for nine months 2018 |
| Research and development | $3.20 million for Q3; $10.78 million for nine months | $2.49 million for Q3 2018; $6.99 million for nine months 2018 |
| General and administrative | $1.49 million for Q3; $5.24 million for nine months | $1.83 million for Q3 2018; $4.08 million for nine months 2018 |
| Cash and cash equivalents | $18.30 million | $19.73 million at December 31, 2018 |
| Cash flow from operations | -$14.90 million for nine months | -$9.01 million for nine months 2018 |
| Debt | None outstanding | None outstanding at December 31, 2018 |
| Working capital / accumulated deficit | $16.3 million / $52.4 million | Not stated here on a comparable basis |
Basic and diluted loss per share was $0.29 for Q3 2019 and $1.19 for the first nine months, compared with $0.43 and $1.20, respectively, in 2018. Profit margins are not meaningful because the company had no revenue. The filing reports stockholders’ equity of $16.4 million.
Material changes versus prior comparable periods
- Nine-month R&D expense rose 54% to $10.78 million, primarily from increased contracted development services, hiring, and stock-based compensation, including accelerated vesting of options.
- Nine-month G&A expense increased 28% to $5.24 million, reflecting payroll, public-company costs, marketing analysis, and rent, partly offset by lower professional fees.
- Operating cash use increased from $9.01 million to $14.90 million for the first nine months. Cash declined by $1.43 million from year-end despite financing proceeds.
- A July 2019 public offering raised approximately $14.03 million gross and $13.0 million net. Shares outstanding increased from 11.47 million at year-end 2018 to 17.10 million at September 30, 2019.
Outlook, risks, contingencies, and unusual items
- Management said available cash was expected to fund operating and capital needs for at least 12 months from issuance of the financial statements; additional capital may be needed thereafter. Failure to raise capital could require reductions in R&D and other costs.
- In an October 29, 2019 update, Eyenovia said it was advancing MicroLine for presbyopia toward Phase III, with VISION trials planned for 2020. It expected to complete enrollment in the MicroPine Phase III CHAPERONE study in 2020 and planned to submit an NDA for MicroStat in 2020.
- Development of MicroProst and MicroTears was deferred while resources were prioritized for MicroLine, MicroPine, and MicroStat. Management estimated the reprioritization could save $1.5 million to $1.9 million in 2020.
- Key risks include clinical-trial and regulatory outcomes, commercialization execution, and dependence on future financing. The company had not completed product development or generated product sales.
- At September 30, $18.05 million of cash and cash equivalents was above FDIC insurance limits. The filing also discloses related-party consulting, engineering, and lease arrangements. Ordinary-course legal claims may arise; the filing reports no legal proceedings.
- Executive employment agreements provide severance in specified termination circumstances, including enhanced benefits following a corporate transaction. No material off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm that Eyenovia, rather than the company named in the request metadata, is the intended issuer.
- Review subsequent clinical and regulatory progress and whether the stated 2020 program milestones were achieved.
- Assess cash burn, the duration of the stated cash runway, and potential future financing needs and dilution.
- Evaluate the implications of the program deferrals, estimated savings, and disclosed related-party arrangements.